Apelin targets gut contraction to control glucose metabolism via the brain

Audren Fournel, Anne Drougard, Thibaut Duparc, Alysson Marlin, Stuart Brierley, Joel Castro, Sophie Le-Gonidec, Bernard Masri, Andre Colom, Alexandre Lucas, Perrine Rousset, Nicolas Cenac, Nathalie Vergnolle, Philippe Valet, Patrice Cani, Claude Knauf

    Research output: Contribution to journalArticlepeer-review

    73 Citations (Scopus)


    Objective The gut-brain axis is considered as a major regulatory checkpoint in the control of glucose homeostasis. The detection of nutrients and/or hormones in the duodenum informs the hypothalamus of the host's nutritional state. This process may occur via hypothalamic neurons modulating central release of nitric oxide (NO), which in turn controls glucose entry into tissues. The enteric nervous system (ENS) modulates intestinal contractions in response to various stimuli, but the importance of this interaction in the control of glucose homeostasis via the brain is unknown. We studied whether apelin, a bioactive peptide present in the gut, regulates ENS-evoked contractions, thereby identifying a new physiological partner in the control of glucose utilisation via the hypothalamus. Design We measured the effect of apelin on electrical and mechanical duodenal responses via telemetry probes and isotonic sensors in normal and obese/diabetic mice. Changes in hypothalamic NO release, in response to duodenal contraction modulated by apelin, were evaluated in real time with specific amperometric probes. Glucose utilisation in tissues was measured with orally administrated radiolabeled glucose. Results In normal and obese/diabetic mice, glucose utilisation is improved by the decrease of ENS/contraction activities in response to apelin, which generates an increase in hypothalamic NO release. As a consequence, glucose entry is significantly increased in the muscle. Conclusions Here, we identify a novel mode of communication between the intestine and the hypothalamus that controls glucose utilisation. Moreover, our data identified oral apelin administration as a novel potential target to treat metabolic disorders.

    Original languageEnglish
    Pages (from-to)258-269
    Number of pages12
    Issue number2
    Publication statusPublished - 2017


    Dive into the research topics of 'Apelin targets gut contraction to control glucose metabolism via the brain'. Together they form a unique fingerprint.

    Cite this